reports
Corbion reports the progress of its share buyback program 27 October –...
Corbion reports the progress of its share buyback program 27 October – 31 October 2025 Corbion hereby reports the transaction details related to its share buyback program announced on 1 September 2025. During the week of 27 October up to and including 31 October 2025 a total of 102.003 shares were repurchased at an average price of €17.6450 for a total amount of €1,799,838.05 To date, the total consideration for shares repurchased amounts to 420,203 shares representing 72.40% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the progre...
- Wim Hoste
Corbion Feedback 3Q results conference call
Below are the key highlights from the 3Q results conference call. 3Q top line was a bit weaker than expected whilst 3Q adjusted EBITDA increased by 11% organically and was in line with our and consensus expectations. Corbion still expects organic EBITDA growth of over 25% which translates into c. € 207m when taking into account the expected negative $ effect (KBCS & CSS € 206m). We continue to appreciate Corbion for its market leadership in lactic acid and growth opportunities within the existin...
- Luis de Toledo Heras
TEMN TEMENOS AG
SOP SOPRA STERIA GROUP SA
OUT1V OUTOKUMPU OYJ
SBMO SBM OFFSHORE NV
KORI KORIAN SA
TYRES NOKIAN RENKAAT OYJ
ASY ASSYSTEM SA
VETO VETOQUINOL SA
PIG HAULOTTE GROUP SA
CDA COMPAGNIE DES ALPES SA
NOEJ NORMA GROUP SE
BB SOCIETE BIC SA
BAMNB KONINKLIJKE BAM GROEP NV
VID VIDRALA SA
MMT METROPOLE TELEVISION SA
AED AEDIFICA SA
SHOT SCANDIC HOTELS GROUP
WAF SILTRONIC AG
MELE MELEXIS NV
ENC ENCE ENERGIA Y CELULOSA SA
SMHN SUESS MICROTEC AG
ALR ALIOR BANK SA
CSM CORBION NV
SAE SHOP APOTHEKE EUROPE NV
ALD ALD SA
CAF CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
ALLFG ALLFUNDS (UK) LTD
ORP ORPEA
SHA SCHAEFFLER AG
- Luis de Toledo Heras
TEMN TEMENOS AG
SOP SOPRA STERIA GROUP SA
OUT1V OUTOKUMPU OYJ
SBMO SBM OFFSHORE NV
KORI KORIAN SA
TYRES NOKIAN RENKAAT OYJ
ASY ASSYSTEM SA
VETO VETOQUINOL SA
PIG HAULOTTE GROUP SA
CDA COMPAGNIE DES ALPES SA
NOEJ NORMA GROUP SE
BB SOCIETE BIC SA
BAMNB KONINKLIJKE BAM GROEP NV
VID VIDRALA SA
MMT METROPOLE TELEVISION SA
AED AEDIFICA SA
SHOT SCANDIC HOTELS GROUP
WAF SILTRONIC AG
MELE MELEXIS NV
ENC ENCE ENERGIA Y CELULOSA SA
SMHN SUESS MICROTEC AG
ALR ALIOR BANK SA
CSM CORBION NV
SAE SHOP APOTHEKE EUROPE NV
ALD ALD SA
CAF CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
ALLFG ALLFUNDS (UK) LTD
ORP ORPEA
SHA SCHAEFFLER AG
- ING Helpdesk
Benelux Morning Notes
Adyen: 3Q25 results – solid net revenue, FY25 guidance reiterated. Aedifica: Guidance raised, positive tenant trends and good portfolio valuation. Ageas: China Taiping Life 3Q25 Solvency much lower, remains solid. Allfunds Group PLC: Strong flows. ASM International: 3Q25 results - disappointing orders, much better margins. Corbion: Iron wills and nerves of steel. Lotus Bakeries: peer Mondelez 3Q25 results. Melexis: 3Q25 results, ongoing gross margin pressure. Staffing: Dutch figs...
- Robert Jan Vos
- Guy Sips
- Lynn Hautekeete
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Hoste
Corbion FIRST LOOK: 3Q EBITDA in line despite weak top line, FY guidan...
3Q top line was a bit weaker than expected whilst 3Q adjusted EBITDA increased by 11% organically and was in line with our and consensus expectations. Corbion still expects organic EBITDA growth of over 25% which translates into c. €207m when taking into account the expected negative $ effect (KBCS & CSS €206m). We continue to appreciate Corbion for its market leadership in lactic acid and growth opportunities within the existing portfolio (food adjacencies, omega-3) whilst looking ahead to the ...
Corbion announces strong YTD EBITDA growth, and EBITDA margin improvem...
Corbion announces strong YTD EBITDA growth, and EBITDA margin improvement of +240 bps; full-year outlook maintained Corbion Q3 2025 Interim Management Statement Corbion, the Amsterdam-listed sustainable ingredients company that champions preservation through application of science, today publishes its results for the first nine months of 2025. Key highlights first nine months 2025: Organic sales growth:+1.2%(Q3: -2.2%) - Volume/mix:+1.7%(Q3: -1.5%) - Price:-0.5%(Q3: -0.7%)Sales€ 957.2 million(Q3: € 311.6 million)Adjusted EBITDA€ 156.3 million(Q3: € 49.7 million)Adju...
Corbion reports the progress of its share buyback program 20 October –...
Corbion reports the progress of its share buyback program 20 October – 24 October 2025 Corbion hereby reports the transaction details related to its share buyback program announced on 1 September 2025. During the week of 20 October up to and including 24 October 2025 a total of 22.669 shares were repurchased at an average price of €17.2559 for a total amount of €391,070.36 To date, the total consideration for shares repurchased amounts to 318,200 shares representing 54.83% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the progress ...
Inventiva: 1 director
A director at Inventiva bought 24,700 shares at 3.295EUR and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Corbion reports the progress of its share buyback program 13 October –...
Corbion reports the progress of its share buyback program 13 October – 17 October 2025 Corbion hereby reports the transaction details related to its share buyback program announced on 1 September 2025. During the week of 13 October up to and including 17 October 2025 a total of 29.981 shares were repurchased at an average price of €16.6672 for a total amount of €499,698.04 To date, the total consideration for shares repurchased amounts to €5,024,854.16 representing 50.25% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the progress o...
- Guy Sips
- Jacob Mekhael
- Mathijs Geerts Danau
- Michiel Declercq
- Thibault Leneeuw
- Wim Hoste
Inventiva Announces the Implementation of a New ATM Program
Inventiva Announces the Implementation of a New ATM Program Daix (France), New York City (New York, United States), October 14, 2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) has filed today a shelf registration statement on Form F-3 (the “Registration Statement”) with the Securities and Exchange Commission (“SEC”). The Registration Statement includes a base prospectus and a sales agreement ...
Inventiva annonce la mise en place d’un nouveau programme « At-The-Mar...
Inventiva annonce la mise en place d’un nouveau programme « At-The-Market » (ATM) Daix (France), New York City (New York, Etats-Unis), le 14 octobre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), annonce ce jour avoir enregistré un document préalable intitulé « Form F-3 » (le « Document d’Enregistrement »), auprès de la U.S. Securities and Exchange Commission (« SEC »), aux Etats...
Corbion reports the progress of its share buyback program 6 October – ...
Corbion reports the progress of its share buyback program 6 October – 10 October 2025 Corbion hereby reports the transaction details related to its share buyback program announced on 1 September 2025. During the week of 6 October up to and including 10 October 2025 a total of 35.578 shares were repurchased at an average price of €16.7661 for a total amount of €596,504.09 To date, the total consideration for shares repurchased amounts to €4,525,155.64 representing 45.25% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the progress of ...
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Thibault Leneeuw
- Wim Lewi
- Jacob Mekhael
Inventiva CMD outlines lanifibranor's differentiation in MASH
Yesterday, Inventiva hosted a CMD which highlighted the potential of lanifibranor in MASH. Our main takeaways are i) the number of diagnosed/treated MASH patients is on the rise, a trend that is expected to continue, ii) the future of the MASH landscape will involve combination therapies with GLP-1 likely being the backbone, and iii) lanifibranor is well positioned to reach a broader set of prescribers incl. endocrinologists thanks to its mechanism and metabolic benefits. We reiterate our € 8 TP...
Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 20...
Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025 Presentation of a comparison between digital and glass slide histology from screening biopsies in the Phase 3 NATiV3 studyPresentation of digital pathology data from preclinical studies with lanifibranor Daix (France), New York City (New York, United States), October 7, 2025 - (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announc...
Inventiva présentera plusieurs abstracts lors du congrès AASLD The Liv...
Inventiva présentera plusieurs abstracts lors du congrès AASLD The Liver Meeting® 2025 Présentation d’une comparaison entre histologie numérique et sur lame des biopsies de screening de l’étude de Phase 3 NATiV3Présentation de pathologie numérique de données précliniques avec lanifibranor Daix (France), New York City (New York, United States), le 7 octobre, 2025 - Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnemen...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.